Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175538 | 1.00 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL1446626 | 0.96 | EGFR (0.71) | EGFRERBB2 | |
| SCHEMBL1446832 | 0.91 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL4419433 | 0.90 | EGFR (0.71) | EGFRERBB2 | |
| SCHEMBL175618 | 0.88 | EGFR (0.73) | EGFRERBB2 | |
| SCHEMBL29623608 | 0.88 | EGFR (0.73) | EGFRERBB2 | |
| SCHEMBL4883905 | 0.88 | ERBB2 (0.82) | EGFRERBB2 | |
| SCHEMBL5904600 | 0.88 | EGFR (0.70) | EGFRERBB2 | |
| SCHEMBL4428969 | 0.88 | ERBB2 (0.68) | EGFRERBB2 | |
| SCHEMBL1446357 | 0.88 | EGFR (0.77) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |